Eli Lilly

News

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Patient using a positive airway pressure mask

Lilly grabs first-ever FDA nod for a sleep apnoea drug

Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.

News

Novo Nordisk sheds billions in value on obesity data

Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.

News

Lilly's Alzheimer's drug Kisunla is cleared in China

Eli Lilly has another approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest drugs market.

News

Ro co-founder and chief executive Zach Reitano

Lilly adds another sales channel for obesity drug Zepbound

Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel.

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

11 blockbuster drugs to look out for in 2025

Lilly grabs first-ever FDA nod for a sleep apnoea drug

Novo Nordisk sheds billions in value on obesity data

Lilly's Alzheimer's drug Kisunla is cleared in China

Lilly adds another sales channel for obesity drug Zepbound

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Eli Lilly

Editor's Picks